Lars Thiebach

Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study

Dirk Arnold, Egbert Eggers, Jens Uhlig, Dietmar Arno Reichert et autres

INTRODUCTION: The non-interventional study (NIS) KORALLE evaluated the effectiveness and safety of bevacizumab in patients with metastatic colorectal carcinoma (mCRC) treated with bevacizumab in combination with fluoropyrimidine-based chemotherapy in the first-line setting and beyond first progression in routine clinical practice. METHODS: This …

de, ch (code pays fourni par la source)

Supplementary Material for: Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study

Dirk Arnold, Egbert Eggers, Jens Uhlig, Dietmar Arno Reichert et autres

Introduction: The non-interventional study (NIS) KORALLE evaluated effectiveness and safety of bevacizumab in patients with metastatic colorectal carcinoma (mCRC) treated with bevacizumab in combination with fluoropyrimidine-based chemotherapy in the first-line setting and beyond first progression in routine clinical practice. Methods: This prospective, …

Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma

Jens Bedke, Axel S. Merseburger, Yohann Loriot, Daniel Castellano et autres

de, fr, es, gb, us, nl, ch, it (code pays fourni par la source)

Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC).

Jens Bedke, Axel S. Merseburger, Yohann Loriot, Daniel Castellano et autres

492 Background: Atezo is an approved therapy for mUC based on the IMvigor210 (IM210) and IMvigor211 (IM211) phase 2 and 3 trials. The single-arm phase 3b SAUL study in a broader patient (pt) population showed consistent efficacy and safety. The value of …

de, fr, es, gb, us, nl, ch (code pays fourni par la source)

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes

Sebastian Stintzing, Sabine Tejpar, Peter Gibbs, Lars Thiebach et autres

Metastatic colorectal carcinoma (mCRC) is a heterogeneous disease with differing outcomes and clinical responses and poor prognosis. CRCs can be characterised by their primary tumour location within the colon. The left-sided colon, derived from the hindgut, includes the distal third of the …

de, be, au, ch, us (code pays fourni par la source)